

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE
13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 1)

Triangle Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

89589H 10 4

(CUSIP Number)

Jose M. de Lasa
Senior Vice President, Secretary
and General Counsel
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-3500
(847) 937-6100

with a copy to:

James T. Lidbury
Mayer, Brown & Platt
190 South LaSalle Street
Chicago, Illinois 60603
(312) 782-0600

(Name, Address and Telephone Number of Persons
Authorized to Receive Notices and Communications)

August 3, 1999

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g),
check the following box []

(Continued on following pages)
(Page 1 of 4 Pages)

CUSIP NO.: 89589H 10 4

13D

- 1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abbott Laboratories (# 36-0698440)
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ()
(b) ()
- 3 SEC USE ONLY
- 4 SOURCE OF FUNDS
WC
- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) or 2(e) ()
- 6 CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois
- 7 SOLE VOTING POWER
6,571,428 shares of Common Stock

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 6,571,428 shares of Common Stock
	10	SHARED DISPOSITIVE POWER 0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
6,571,428 shares of Common Stock

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES ()

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
17.6%

14 TYPE OF REPORTING PERSON
CO

This Amendment No. 1 (this "Amendment") amends the Schedule 13D filed by Abbott Laboratories, an Illinois corporation ("Abbott") on June 2, 1999 (the "Original Schedule 13D"). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings assigned to those terms in the Original Schedule 13D.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The aggregate purchase price for the purchase by Abbott described herein of 6,571,428 shares of the common stock, par value \$0.001 per share, (the "Common Stock") of Triangle Pharmaceuticals, Inc. (the "Issuer") was \$118,285,704. The source of such funds was the working capital of Abbott.

ITEM 4. PURPOSE OF THE TRANSACTION

As previously disclosed, pursuant to the Stock Purchase Agreement dated as of June 2, 1999 between Abbott and the Issuer, Abbott agreed to purchase 6,571,428 shares of Common Stock at a purchase price of \$118,285,704. On August 3, 1999 Abbott and the Issuer consummated the transactions contemplated by the Stock Purchase Agreement, including the purchase by Abbott of 6,571,428 shares of Common Stock. Also on August 3, 1999 the Issuer and Abbott entered into the Supply Agreement and the closings were held under the Collaboration Agreement and the Co-Promotion Agreement.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

(a) Abbott is the beneficial owner of all 6,571,428 shares of Common Stock. Such Shares represent 17.6% of the total outstanding shares of Common Stock.

(b) Abbott has the sole power to vote and to dispose of all 6,571,428 shares of Common Stock.

(c) Other than the execution of the Stock Purchase Agreement on June 2, 1999 and the purchase of 6,571,428 shares of Common Stock on August 3, 1999, Abbott has not effected any transactions in the Common Stock in the past 60 days.

(d)-(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 10, 1999

ABBOTT LABORATORIES

By: /s/ Gary L. Flynn

Name: Gary L. Flynn

Title: Vice President & Controller